CD44及CD24在乳腺癌组织中的表达及与临床病理特征的关系研究

目的:探讨肿瘤标志因子CD44及CD24在乳腺癌组织中的表达及与临床病理特征的关系。方法:选择从2015年1月到2017年1月在我院接受手术治疗的乳腺癌患者80例纳入本次研究,另选同期在我院治疗的导管原位癌患者30例,小叶增生患者20例及导管单纯增生患者20例的组织提取标本进行对照,分析CD44及CD24在乳腺癌组织和不同病变类型中的表达,并分析CD44~+/CD24~-细胞在癌症免疫分型中的表达以及CD44~+/CD24~-细胞与乳腺浸润导管癌相关病理特征的关系。结果:乳腺癌组织内的CD44阳性率为52.50%,CD24的阳性率为57.50%,均显著高于癌旁组织的11.25%和15.00%,差异均有统计学意义(均P0.05)。CD44及CD24在导管原位癌及乳腺浸润导管癌中的阳性率高于小叶增生和导管单纯增生,导管原位癌的阳性率高于乳腺浸润导管癌,差异均有统计学意义(均P0.05),且CD44在乳腺浸润导管癌不同分化类型中的阳性率差异有统计学意义(P0.05)。CD24在乳腺浸润导管癌不同分化类型中的阳性率差异不显著(P0.05)。CD44~+/CD24~-细胞在不同癌症免疫分型以及不同分化中的阳性率比较差异均有统计学意义(P0.05)。CD44~+/CD24~-细胞与乳腺浸润导管癌患者的年龄、月经状态、肿瘤直径、淋巴结转移以及远处转移之间均无明显关系(均P0.05)。结论:CD44及CD24在乳腺癌组织内存在较高的阳性率,且CD44~+/CD24~-在乳腺原位癌及低分化的乳腺癌组织内具有更高的阳性率,临床上可尝试通过监测CD44~+/CD24~-的阳性表达情况评价患者的病情及预后。

Expression of CD44 and CD24 in Breast Cancer Tissues and Their Relationship with Clinicopathological Features

ABSTRACT Objective: To study the expression of CD44 and CD24 in breast cancer tissues and their relationship with clinicopathological features. Methods: A total of 80 patients with breast cancer, who were received surgical treatment in Cangzhou People''s Hospital of Hebei Province from January 2015 to January 2017, were enrolled in this study; 30 patients with ductal carcinoma in situ, 20 patients with lobular hyperplasia, 20 patients with simple ductal hyperplasia,admitted to in this hospital in the same period, were selected. Specimens were extracted from cancer patients and hyperplastic patients and compared. The expression of CD44 and CD24 in breast cancer tissues and different lesion types were analyzed, and the expression of CD44⁺/CD24^- cells in the cancer immune typing and the relationship between CD44⁺/CD24^- cells and the pathological features of breast invasive ductal carcinoma were analyzed. Results: The positive expression rates of CD44 and CD24 in breast cancer tissues were 52.50% and 57.50%, respectively, which were significantly higher than those(11.25% and 15.00%) in the adjacent tissues, the difference was statistically significant (P<0.05).The positive rates of CD44 and CD24 in ductal carcinoma in situ and in breast invasive ductal carcinoma were higher than those in lobular hyperplasia and in simple ductal hyperplasia, the positive rate of ductal carcinoma in situ was higher than that of breast invasive ductal carcinoma,the difference was statistically significant (all P<0.05).The positive rate of CD44 in different types of breast invasive ductal carcinoma was statistically significant (P<0.05), and there was no significant difference in the positive rate of CD24 in different types of breast invasive ductal carcinoma (P>0.05). There were significant differences in the positive rates of CD44⁺ /CD24^- cells in different types of cancer immunology and differentiation (P<0.05). There was no significant relationship between CD44⁺ /CD24^- cells and age, menstrual status, tumor size, lymph node metastasis and distant metastasis in patients with breast invasive ductal carcinoma (P<0.05). Conclusion: CD44 and CD24 have higher positive expression rate in breast cancer tissues, and CD44⁺ /CD24^- has a higher positive expression rate in breast carcinoma in situ and poorly differentiated breast invasive ductal carcinoma. The patient''s condition and prognosis were evaluated by monitoring the positive expression of CD44⁺ /CD24^- in clinic.